|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"dayyani f"
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國家衛生研究院 |
2024-08 |
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study
|
Oh, DY;He, AR;Bouattour, M;Okusaka, T;Qin, S;Chen, LT;Kitano, M;Lee, CK;Kim, JW;Chen, MH;Suksombooncharoen, T;Ikeda, M;Lee, MA;Chen, JS;Potemski, P;Burris, HA, 3rd;Ostwal, V;Tanasanvimon, S;Morizane, C;Zaucha, RE;McNamara, MG;Avallone, A;Cundom, JE;Breder, V;Tan, B;Shimizu, S;Tougeron, D;Evesque, L;Petrova, M;Zhen, DB;Gillmore, R;Gupta, VG;Dayyani, F;Park, JO;Buchschacher, GL, Jr.;Rey, F;Kim, H;Wang, J;Morgan, C;Rokutanda, N;Żotkiewicz, M;Vogel, A;Valle, JW |
| 臺大學術典藏 |
2022-08-19T06:48:43Z |
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
|
Wang Y.; Burgoyne A.M.; Dayyani F.; Spahn J.; Verret W.; Finn R.S.; Toh H.C.; Lujambio A.; Yau T.; Kaseb A.O.; Ryoo B.-Y.; He A.R.; CHIH-HUNG HSU; Zhang W.; Koeppen H.; Lu S.; Guan Y.; de Galarreta M.R.; Abbas A.R.; Zhu A.X. |
| 國立成功大學 |
2022 |
Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
|
Zhu, A.X.;Dayyani, F.;Yen, C.-J.;Ren, Z.;Bai, Y.;Meng, Z.;Pan, H.;Dillon, P.;Mhatre, S.K.;Gaillard, V.E.;Hernandez, S.;Kelley, R.K.;Sangro, B. |
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
